About Lifestyle Drugs Market
Lifestyle disease is associated with the way an individual or group of people live. Some of the lifestyle diseases include depression, sexual dysfunction, anti-aging, baldness, and obesity.
Technavio’s analysts forecast the global lifestyle drugs market to grow at a CAGR of 2.87% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global lifestyle drugs market for 2017-2021. To calculate the market size, the report considers sales of lifestyle drugs in the market.
The market is divided into the following segments based on geography:
• Americas
• EMEA
• APAC
Technavio's report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Allergan
• BMS
• Eli Lilly
• Pfizer
Other prominent vendors
• Acerus Pharmaceuticals
• Alkermes
• Amorepacific
• AndroScience
• Anterios
• AstraZeneca
• Avanir Pharmaceuticals
• Avolynt
• Celtaxsys
• Cerecor
• Corcept Therapeutics
• Cosmo Pharmaceuticals
• CTC Bio
• Dermira
• Dong-A ST
• Euthymics Bioscience
• Foamix
• Follicum
• Forendo Pharma
• Futura Medical Developments
• Galderma
• Hanmi Pharmaceutical
• Incyte
• Intrepid Therapeutics
• Ion Channel Innovations
• iX Biopharma
• Johnson & Johnson
• Legacy Healthcare
• LEO Pharma
• H. Lundbeck
• Luye America Pharmaceuticals
• Merck
• Minerva Neurosciences
• MSI Methylation Sciences
• Neuralstem
• Novan
• Novartis
• Novo-Nordisk
• Palatin Technologies
• Paratek Pharmaceuticals
• Photocure
• Revance Therapeutics
• Rhythm Pharmaceuticals
• S1 Biopharma
• Sage Therapeutics
• Samumed
• Sanofi
• Sigma-Tau Pharmaceuticals
• Strategic Science & Technologies
• Sumitomo Dainippon Pharma
• Takeda
• TetraLogic Pharmaceuticals
• TherapeuticsMD
• Valeant Pharmaceuticals
• VistaGen Therapeutics
• VIVUS
• XBiotech
• Yuhan
• Zafgen
Market driver
• Lifestyle changes
• For a full, detailed list, view our report
Market challenge
• Patent expiries
• For a full, detailed list, view our report
Market trend
• Increase in M&A
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Key market highlights
PART 05: An overview of lifestyle diseases
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by therapy area
• Depression
• Dermatology (acne, anti-aging, and baldness)
• Sexual dysfunction
• Obesity
PART 09: Geographical segmentation
• Lifestyle drugs market in Americas
• Lifestyle drugs market in EMEA
• Lifestyle drugs market in APAC
PART 10: Market drivers
• Lifestyle changes
• Development of novel therapeutics
• Increasing demand from older population
PART 11: Impact of drivers
PART 12: Market challenges
• Patent expiries
• Side effects coupled with product recalls
• Presence of alternative therapies and treatments
PART 13: Impact of drivers and challenges
PART 14: Market trends
• Increase in M&A
• Growing focus on development of drugs for new indications
• Emerging lifestyle diseases
PART 15: Vendor landscape
• Competitive scenario
PART 16: Key vendor analysis
• Allergan
• BMS
• Eli Lilly
• Pfizer
• Other prominent vendors
PART 17: Appendix
• List of abbreviation
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Global lifestyle drugs market snapshot
Exhibit 02: Global lifestyle drugs market 2016-2021 ($ billions)
Exhibit 03: Opportunity analysis in global lifestyle drugs market
Exhibit 04: Five forces analysis
Exhibit 05: Pipeline analysis of vendors in Phase III
Exhibit 06: Key pipeline drugs for depression 2016
Exhibit 07: Key pipeline drugs for dermatology (anti-aging, baldness, and acne) 2016
Exhibit 08: Key pipeline drugs for sexual dysfunction 2016
Exhibit 09: Key pipeline drugs for obesity
Exhibit 10: Global depression drugs market 2016-2021 ($ billions)
Exhibit 11: Global dermatology lifestyle drugs market 2016-2021 ($ billions)
Exhibit 12: Global sexual dysfunction drugs market 2016-2021 ($ billions)
Exhibit 13: Global obesity drugs market 2016-2021 ($ billions)
Exhibit 14: Segmentation of global lifestyle drugs market by geography 2016 and 2021
Exhibit 15: Global lifestyle drugs market revenue by geography 2016-2021 ($ billions)
Exhibit 16: Market scenario in Americas
Exhibit 17: Lifestyle drugs market in Americas 2016-2021 ($ billions)
Exhibit 18: Market scenario in EMEA
Exhibit 19: Lifestyle drugs market in EMEA 2016-2021 ($ billions)
Exhibit 20: Market scenario in APAC
Exhibit 21: Lifestyle drugs market in APAC 2016-2021 ($ billions)
Exhibit 22: Impact of drivers
Exhibit 23: Impact of drivers and challenges
Exhibit 24: Competitive structure analysis of global lifestyle drugs market 2016
Exhibit 25: Competitive analysis of global lifestyle drugs market
Exhibit 26: Market penetration of various lifestyle drug manufacturers worldwide 2016
Exhibit 27: Strategic success factors of companies in global lifestyle drugs market
Exhibit 28: Allergan: Key highlights
Exhibit 29: Allergan: Strength assessment
Exhibit 30: Allergan: Strategy assessment
Exhibit 31: Allergan: Opportunity assessment
Exhibit 32: BMS: Strength assessment
Exhibit 33: BMS: Strategy assessment
Exhibit 34: BMS: Opportunity assessment
Exhibit 35: BMS: YoY and growth rate of Abilify 2013-2015 ($ billions)
Exhibit 36: Eli Lilly: Key highlights
Exhibit 37: Eli Lilly: Strength assessment
Exhibit 38: Eli Lilly: Strategy assessment
Exhibit 39: Eli Lilly: Opportunity assessment
Exhibit 40: Eli Lilly: YoY and growth rate of Cymbalta 2013-2015 ($ millions)
Exhibit 41: Eli Lilly: YoY and growth rate of Zyprexa 2013-2015 ($ millions)
Exhibit 42: Eli Lilly: YoY and growth rate of Strattera 2013-2015 ($ millions)
Exhibit 43: Eli Lilly: YoY and growth rate of Cialis 2013-2015 ($ millions)
Exhibit 44: Pfizer: Key highlights
Exhibit 45: Pfizer: Strength assessment
Exhibit 46: Pfizer: Strategy assessment
Exhibit 47: Pfizer: Opportunity assessment
Exhibit 48: Pfizer: YoY and growth rate of Pristiq 2013-2015 ($ millions)
Exhibit 49: Pfizer: YoY and growth rate of Zoloft 2013-2015 ($ millions)
Exhibit 50: Pfizer: YoY and growth rate of Effexor 2013-2015 ($ millions)
Exhibit 51: Pfizer: YoY and growth rate of Viagra 2013-2015 ($ millions)
